GUIZHOU XINBANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.85 CNY | +1.05% |
|
+4.34% | -13.29% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,819 | 8,472 | 13,431 | 14,423 | 9,136 | 8,560 |
| Enterprise Value (EV) 1 | 9,404 | 11,084 | 15,065 | 15,214 | 9,630 | 8,589 |
| P/E ratio | -5.11 x | 35 x | 77.1 x | 49.5 x | 39.2 x | 29.6 x |
| Yield | - | - | - | 0.81% | 1.28% | 1.35% |
| Capitalization / Revenue | 1.04 x | 1.27 x | 2.3 x | 2.23 x | 1.44 x | 1.32 x |
| EV / Revenue | 1.43 x | 1.67 x | 2.58 x | 2.35 x | 1.52 x | 1.33 x |
| EV / EBITDA | 14.3 x | 15.6 x | 23.8 x | 19.9 x | 17.1 x | 14.1 x |
| EV / FCF | -11.7 x | 24 x | 27.9 x | -555 x | 30.6 x | 15.2 x |
| FCF Yield | -8.54% | 4.16% | 3.59% | -0.18% | 3.27% | 6.59% |
| Price to Book | 1.37 x | 1.74 x | 2.73 x | 2.18 x | 1.34 x | 1.24 x |
| Nbr of stocks (in thousands) | 1,667,229 | 1,613,800 | 1,583,852 | 1,943,852 | 1,943,852 | 1,927,832 |
| Reference price 2 | 4.090 | 5.250 | 8.480 | 7.420 | 4.700 | 4.440 |
| Announcement Date | 4/28/19 | 4/29/20 | 3/29/21 | 4/14/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6,580 | 6,655 | 5,846 | 6,472 | 6,350 | 6,461 |
| EBITDA 1 | 659.5 | 711 | 632.3 | 763.1 | 563.8 | 611 |
| EBIT 1 | 447.1 | 476.1 | 403.6 | 528.6 | 332.8 | 386.4 |
| Operating Margin | 6.79% | 7.15% | 6.9% | 8.17% | 5.24% | 5.98% |
| Earnings before Tax (EBT) 1 | -1,211 | 331.5 | 267.5 | 421.1 | 313.4 | 396 |
| Net income 1 | -1,297 | 236.3 | 173.5 | 272.9 | 224.5 | 287.2 |
| Net margin | -19.7% | 3.55% | 2.97% | 4.22% | 3.54% | 4.45% |
| EPS 2 | -0.8000 | 0.1500 | 0.1100 | 0.1500 | 0.1200 | 0.1500 |
| Free Cash Flow 1 | -803.6 | 461.3 | 540.9 | -27.42 | 314.7 | 566.2 |
| FCF margin | -12.21% | 6.93% | 9.25% | -0.42% | 4.96% | 8.76% |
| FCF Conversion (EBITDA) | - | 64.88% | 85.55% | - | 55.81% | 92.68% |
| FCF Conversion (Net income) | - | 195.22% | 311.73% | - | 140.17% | 197.13% |
| Dividend per Share | - | - | - | 0.0600 | 0.0600 | 0.0600 |
| Announcement Date | 4/28/19 | 4/29/20 | 3/29/21 | 4/14/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2,585 | 2,611 | 1,634 | 791 | 493 | 29.4 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.92 x | 3.673 x | 2.584 x | 1.036 x | 0.8751 x | 0.0481 x |
| Free Cash Flow 1 | -804 | 461 | 541 | -27.4 | 315 | 566 |
| ROE (net income / shareholders' equity) | -21.5% | 5.16% | 4.32% | 6.23% | 3.86% | 4.98% |
| ROA (Net income/ Total Assets) | 2.45% | 2.8% | 2.51% | 3.42% | 2.14% | 2.54% |
| Assets 1 | -52,916 | 8,447 | 6,907 | 7,967 | 10,480 | 11,324 |
| Book Value Per Share 2 | 2.980 | 3.030 | 3.110 | 3.410 | 3.500 | 3.590 |
| Cash Flow per Share 2 | 0.9700 | 0.7700 | 1.120 | 0.3200 | 0.4600 | 0.4200 |
| Capex 1 | 264 | 208 | 138 | 254 | 159 | 136 |
| Capex / Sales | 4% | 3.12% | 2.36% | 3.92% | 2.5% | 2.1% |
| Announcement Date | 4/28/19 | 4/29/20 | 3/29/21 | 4/14/22 | 4/17/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.29% | 1.01B | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 002390 Stock
- Financials Guizhou Xinbang Pharmaceutical Co., Ltd.
